1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Class Dismissed: US FDA’s ‘Dean’ Bob Temple Retiring After 52 Years

 
• By Michael McCaughan

Robert Temple, the US FDA’s most experienced drug regulator, is currently serving an emeritus role at the agency. The immediate impact of his departure will be mostly symbolic, but still unsettling.

The departure of Robert Temple, deputy CDER director for clincal science, marks the end of an era for the FDA. (File)
Key Takeaways
  • Robert Temple, a leader in drug regulation at the FDA for decades, will retire at the end of 2024.
  • Former Acting Commissioner Janet Woodcock said Temple and others “basically invented the regulatory standards for clinical evidence generation.”
  • Temple’s departure comes at a potential inflection point for the FDA as the Trump Administration prepares to take over.

The US Food and Drug Administration will enter 2025 without Robert Temple,

After an amazing 52 years at the agency, Temple will retire at the end of the year, Center for Drug Evaluation and Research Director Patrizia

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

US FDA Legislative Lead Calls For User Fee Reforms As Renewal Talks Near

 
• By Sarah Karlin-Smith

Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.

Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation

 
• By Barnaby Pickering

Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.

More from R&D

UK MHRA’s Clinical Trial Lead On Combined Reviews, The Notification Scheme & Increasing Diversity

 
• By Eliza Slawther

In light of the UK’s MHRA announcing a major overhaul of its clinical trial legislation, the agency’s deputy director for clinical investigations and trials Andrea Manfrin tells the Pink Sheet what sponsors can expect from the new regulation.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.